ATP5PO

Across TCGA pan-cancer cohorts, ATP5PO mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP5PO data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP5PO mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATP5PO expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and OV are the cancer types where ATP5PO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.975	0.802	.003	35	view →
PDAC	OS	Median	All	0.618	0.367	.004	20	view →
OV	DFS	Quartile	All	0.896	0.456	.014	8	view →
LUAD	DFS	Tertile	All	0.398	0.737	.011	7	view →
GBM	OS	Tertile	All	0.956	0.758	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP5PO–LSCC (OS)

Open the LSCC breakdown →